By Josh White
Date: Monday 11 May 2026
(Sharecast News) - 4basebio said on Monday that it had commercially launched a high-capacity single-stranded DNA product line aimed at supporting the development of gene editing, cell engineering and nucleic acid-based medicines.
The AIM-traded synthetic DNA manufacturer said the platform was built on its proprietary enzymatic manufacturing process and was designed...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news